Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
12 December 2019 | Story Rulanzen Martin | Photo Johan Roux
Dionne
Dr Dionne van Reenen received her PhD during the December Graduation Ceremonies at the UFS

Very seldom in modern history do we try to critically think about how our bodies and even more those of women are presented in modern popular culture. Through her PhD research project, Dionne van Reenen attempts to critically analyse ideological formations of the body in performance and its discursive distribution in the consumption of contemporary popular media, adding to existing literature and research on the topic.

Her dissertation is titled Performing the Erotic: (Re)presenting the Body in Popular Culture.

Van Reenen, a senior researcher at the Unit for Institutional Change and Social Justice at the University of the Free State (UFS), received her PhD qualification specialising in English on Wednesday 11 December 2019 during the final ceremony of the December Graduation.

Van Reenen has extensive experience in all areas of education. Her work at the Unit for Institutional Change and Social Justice is interdisciplinary, involving both everyday and institutional politics. She also holds a Master’s degree in Philosophy, which she obtained in 2013 from the UFS. In 2016, she chaired the UFS Language Policy Review Committee and established the Gender and Sexual Equity Office, which formulated the Sexual Harassment, Misconduct, and Violence Policy at the UFS. 

Changing of social constructs in media consumption

“My study focuses on performative framings of social constructs of gender, race, and class (along with size, age, and ability) in the ordering processes of society,” she says.  These performative framings in are in turn sustained by the (re)presentation of eroticised bodies in popular visual media in the 21st century. “These framings and orderings are critiqued as nothing new, but simply entertainment product that is trading in ideologies and stereotypes that have long been in sociocultural circulation, and they affect how people think, speak and act.” 

The study also shows that the dynamics of ‘virtuality’ and ‘visuality’ in the digital age are altering traditional demarcations of space, place, time, and community, and have paved the way for formations of global cultures that are, at the same time, informative, expedient, empowering, homogenising, prescriptive, and imperialising.

Whilst the #MeToo movement focused more on gender-based violence, gender inequality, and sexual violence, which are big social issues and do not exist in isolation, Van Reenen used her critical philosophical training to understand how, in the current era, the dominant discourse on representations of the body, particularly marginalised bodies, has been constructed at the popular level. 

With every PhD research dissertation the candidate’s main aim is to add new knowledge to a discipline. For Van Reenen, it is important that her research can contribute to a change in social and cultural constructs by re-imagining the (re)presentations of the body in popular media.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept